PE20050870A1 - Solvato acetonico del dimetoxi docetaxel y su procedimiento de preparacion - Google Patents

Solvato acetonico del dimetoxi docetaxel y su procedimiento de preparacion

Info

Publication number
PE20050870A1
PE20050870A1 PE2004000799A PE2004000799A PE20050870A1 PE 20050870 A1 PE20050870 A1 PE 20050870A1 PE 2004000799 A PE2004000799 A PE 2004000799A PE 2004000799 A PE2004000799 A PE 2004000799A PE 20050870 A1 PE20050870 A1 PE 20050870A1
Authority
PE
Peru
Prior art keywords
water
acetone
solution
dimetoxy
docetaxel
Prior art date
Application number
PE2004000799A
Other languages
English (en)
Spanish (es)
Inventor
Eric Didier
Marc-Antoine Perrin
Original Assignee
Aventis Pharma Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34224354&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20050870(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Aventis Pharma Sa filed Critical Aventis Pharma Sa
Publication of PE20050870A1 publication Critical patent/PE20050870A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D305/00—Heterocyclic compounds containing four-membered rings having one oxygen atom as the only ring hetero atoms
    • C07D305/14—Heterocyclic compounds containing four-membered rings having one oxygen atom as the only ring hetero atoms condensed with carbocyclic rings or ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Epoxy Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Cephalosporin Compounds (AREA)
PE2004000799A 2003-09-19 2004-08-19 Solvato acetonico del dimetoxi docetaxel y su procedimiento de preparacion PE20050870A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR0311016A FR2859996B1 (fr) 2003-09-19 2003-09-19 Solvat acetonique du dimethoxy docetaxel et son procede de preparation

Publications (1)

Publication Number Publication Date
PE20050870A1 true PE20050870A1 (es) 2005-11-21

Family

ID=34224354

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2004000799A PE20050870A1 (es) 2003-09-19 2004-08-19 Solvato acetonico del dimetoxi docetaxel y su procedimiento de preparacion

Country Status (37)

Country Link
US (1) US7241907B2 (enExample)
EP (1) EP1667986B1 (enExample)
JP (1) JP5010279B2 (enExample)
KR (1) KR101123588B1 (enExample)
CN (1) CN100429207C (enExample)
AR (1) AR045667A1 (enExample)
AU (1) AU2004274212B2 (enExample)
BE (1) BE2013C036I2 (enExample)
BR (1) BRPI0414492A8 (enExample)
CA (1) CA2539309A1 (enExample)
CR (1) CR8292A (enExample)
CY (2) CY1114575T1 (enExample)
DK (1) DK1667986T3 (enExample)
ES (1) ES2403149T4 (enExample)
FR (2) FR2859996B1 (enExample)
HR (1) HRP20130322T1 (enExample)
HU (1) HUS1300025I1 (enExample)
IL (1) IL174240A (enExample)
LU (1) LU92172I2 (enExample)
MA (1) MA28045A1 (enExample)
ME (2) ME00054B (enExample)
MX (1) MXPA06002639A (enExample)
MY (1) MY136668A (enExample)
NO (2) NO335997B1 (enExample)
NZ (1) NZ545835A (enExample)
PA (1) PA8612401A1 (enExample)
PE (1) PE20050870A1 (enExample)
PL (1) PL1667986T3 (enExample)
PT (1) PT1667986E (enExample)
RS (2) RS20060189A (enExample)
RU (1) RU2342373C2 (enExample)
SI (1) SI1667986T1 (enExample)
TN (1) TNSN06086A1 (enExample)
TW (1) TWI382022B (enExample)
UA (1) UA87115C2 (enExample)
WO (1) WO2005028462A1 (enExample)
ZA (1) ZA200602255B (enExample)

Families Citing this family (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20080100264A (ko) * 2006-03-21 2008-11-14 닥터 레디스 레보러터리즈 리미티드 도세탁셀의 다형체와 그 제조방법
US7855591B2 (en) * 2006-06-07 2010-12-21 Atmel Corporation Method and system for providing a charge pump very low voltage applications
US7652522B2 (en) * 2006-09-05 2010-01-26 Atmel Corporation High efficiency low cost bi-directional charge pump circuit for very low voltage applications
US20080176958A1 (en) 2007-01-24 2008-07-24 Insert Therapeutics, Inc. Cyclodextrin-based polymers for therapeutics delivery
FR2926551A1 (fr) * 2008-01-17 2009-07-24 Aventis Pharma Sa Formes cristallines du dimethoxy docetaxel et leurs procedes de preparation
AU2013205442B2 (en) * 2008-01-17 2016-05-12 Aventis Pharma S.A. Crystalline forms of dimethoxy docetaxel and methods for preparing same
KR101671537B1 (ko) 2008-08-11 2016-11-01 넥타르 테라퓨틱스 다분지형 중합체 알카노에이트 컨쥬게이트
FR2945211A1 (fr) * 2009-05-06 2010-11-12 Sanofi Aventis Combinaison antitumorale comprenant la cabazitaxel et la capecitabine
AU2015200149B2 (en) * 2009-10-29 2016-12-01 Aventis Pharma S.A. Novel antitumoral use of cabazitaxel
CA2708489A1 (en) * 2009-10-29 2011-04-29 Aventis Pharma S.A. Use of cabazitaxel and a prednisone or a prednisolone in the treatment of prostate cancer
AU2010310986A1 (en) 2009-10-29 2012-06-14 Aventis Pharma S.A. Novel antitumoral use of cabazitaxel
US10894087B2 (en) 2010-12-22 2021-01-19 Nektar Therapeutics Multi-arm polymeric prodrug conjugates of cabazitaxel-based compounds
US20130331443A1 (en) 2010-12-22 2013-12-12 Nektar Therapeutics Multi-arm polymeric prodrug conjugates of taxane-based compounds
CN103764637A (zh) * 2011-04-12 2014-04-30 普拉斯化学品有限公司 卡巴他赛的固态形式及其制备方法
WO2013024495A1 (en) * 2011-08-18 2013-02-21 Dr. Reddys Laboratories Limited Pharmaceutical formulations of cabazitaxel
TWI526437B (zh) * 2011-09-09 2016-03-21 台灣神隆股份有限公司 卡巴他賽之結晶型
US8722900B2 (en) 2011-10-31 2014-05-13 Scinopharm Taiwan, Ltd. Process for cabazitaxel, and intermediates thereof
DE112012004569T5 (de) 2011-11-01 2014-08-14 Fresenius Kabi Oncology Ltd. Amorphe Form von Cabazitaxel und Verfahren zum Herstellen davon
PL2785701T3 (pl) 2011-11-28 2019-08-30 Fresenius Kabi Oncology Limited Krystaliczna postać kabazytakselu i sposób jej otrzymywania
EP2791122B1 (en) 2011-12-13 2019-01-23 Aventis Pharma S.A. Crystalline form of cabazitaxel and process for preparing the same
US9403785B2 (en) 2012-01-03 2016-08-02 Shilpa Medicare Limited Process for preparing amorphous cabazitaxel
WO2013117683A1 (en) * 2012-02-10 2013-08-15 Aventis Pharma S.A. New pediatric uses of cabazitaxel
US9394266B2 (en) 2012-03-08 2016-07-19 IVAX International GmbH Solid state forms of cabazitaxel and processes for preparation thereof
CN102675257B (zh) * 2012-05-10 2014-07-02 上海金和生物技术有限公司 一种卡巴他赛晶体及其制备方法
CN102746258B (zh) 2012-07-25 2015-02-04 重庆泰濠制药有限公司 卡巴他赛的结晶形式及其制备方法
EP2880021A4 (en) 2012-07-31 2015-06-17 Yung Shin Pharm Ind Co Ltd AMORPHIC CABACITAXEL
EP2884963B1 (en) 2012-08-15 2017-12-27 Yung Shin Pharm. Ind. Co. Ltd. Stable pharmaceutical formulation of cabazitaxel
CN103664836B (zh) * 2012-09-20 2016-04-20 齐鲁制药有限公司 7β,10β-二甲氧基多西紫杉醇氘代丙酮合物的晶型A及其制备方法
WO2014055493A1 (en) 2012-10-02 2014-04-10 Cerulean Pharma Inc. Methods and systems for polymer precipitation and generation of particles
CN103804323A (zh) * 2012-11-14 2014-05-21 上海希迈医药科技有限公司 一种卡巴他赛溶剂化物及其制备方法和应用
CN103058960B (zh) * 2012-12-12 2014-12-10 江苏奥赛康药业股份有限公司 卡巴他赛多晶型形式及其制备方法
EP2743264A1 (en) 2012-12-13 2014-06-18 INDENA S.p.A. New crystalline form of cabazitaxel, process for the preparation and pharmaceutical compositions thereof
CN103910698B (zh) * 2012-12-30 2016-01-20 上海医药工业研究院 卡巴他赛丙酮合物及其结晶
CN103910696B (zh) * 2012-12-30 2016-01-20 上海医药工业研究院 卡巴他赛异丙醚合物及其结晶
EP2777691A1 (en) 2013-03-14 2014-09-17 Pharmachemie B.V. Taxoid - Purification of Liquid Excipients
EP2815749A1 (en) 2013-06-20 2014-12-24 IP Gesellschaft für Management mbH Solid form of 4-amino-2-(2,6-dioxopiperidine-3-yl)isoindoline-1,3-dione having specified X-ray diffraction pattern
CN104277014A (zh) * 2013-07-04 2015-01-14 北京新天宇科技开发有限公司 二甲氧基多西紫杉醇一丙酮化物的稳定转化物及其结晶形式、以及它们的制备方法
WO2015000165A1 (zh) * 2013-07-04 2015-01-08 北京新天宇科技开发有限公司 二甲氧基多西紫杉醇一丙酮化物的稳定转化物及其结晶形式、以及它们的制备方法
EP2865674A1 (en) 2013-10-23 2015-04-29 INDENA S.p.A. Crystalline solvate forms of Cabazitaxel
EP2865675A1 (en) 2013-10-23 2015-04-29 INDENA S.p.A. A crystalline anhydrous form of Cabazitaxel, process for the preparation and pharmaceutical compositions thereof
CN103601704B (zh) * 2013-11-22 2015-05-06 石家庄智恒医药科技有限公司 无定形卡巴他赛的制备
WO2016113752A2 (en) 2015-01-12 2016-07-21 Emcure Pharmaceuticals Limited Liquid formulation of cabazitaxel
WO2016133387A1 (en) 2015-02-17 2016-08-25 Erasmus University Medical Center Rotterdam Use of cabazitaxel in the treatment of prostate cancer
EP3093014A1 (en) * 2015-05-13 2016-11-16 Aventis Pharma S.A. Cabazitaxel and its use for treating cancer
US10188626B2 (en) 2015-11-03 2019-01-29 Cipla Limited Stabilized cabazitaxel formulations
CN110312721A (zh) 2016-11-29 2019-10-08 显莎制药公司 墨蝶呤的多晶型物
WO2018102315A1 (en) 2016-11-29 2018-06-07 Censa Pharmaceuticals Inc. Polymoprhs of sepiapterin and salts thereof
MX2020002271A (es) 2017-09-01 2020-10-05 Ptc Therapeutics Mp Inc Composiciones farmaceuticas que comprenden sepiapterina y sus usos de las mismas.
JP7778477B2 (ja) 2018-05-30 2025-12-02 ピーティーシー セラピューティクス エムピー,インコーポレイテッド セピアプテリンの薬学的に許容される塩
CA3102105A1 (en) 2018-05-30 2019-12-05 Ptc Therapeutics Mp, Inc. Compositions and methods for increasing tetrahydrobiopterin plasma exposure
JP7502197B2 (ja) 2018-05-30 2024-06-18 ピーティーシー セラピューティクス エムピー,インコーポレイテッド セピアプテリン血漿曝露を増加させるための方法
WO2020249507A1 (en) 2019-06-11 2020-12-17 Indena S.P.A. Anhydrous crystalline form of cabazitaxel, a process for its preparation and pharmaceutical compositions containing it
EP3808345A1 (en) 2019-10-15 2021-04-21 Sanofi Mature IP Cabazitaxel in mcrpc patients previously treated with docetaxel and who failed a prior androgen signaling targeted inhibitor agent
EP3797834A1 (en) 2019-09-25 2021-03-31 Sanofi Mature IP Cabazitaxel in mcrpc patients previously treated with docetaxel and who failed a prior androgen signaling targeted inhibitor agent

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5766635A (en) * 1991-06-28 1998-06-16 Rhone-Poulenc Rorer S.A. Process for preparing nanoparticles
FR2722191B1 (fr) * 1994-07-08 1996-08-23 Rhone Poulenc Rorer Sa Procede de preparation du trihydrate du (2r,3s)-3-tertbutoxycarbonylamino-2-hydroxy-3-phenylpropionate de 4-acetoxy2alpha-benzoyloxy-5beta,20epoxy-1,7beta,10beta trihydroxy-9-oxo-tax-11-en-13alpha-yle
DE4425978C1 (de) * 1994-07-22 1995-11-23 Karlsruhe Forschzent Verfahren zur Herstellung keramischer Mikrostrukturen
MA23823A1 (fr) * 1995-03-27 1996-10-01 Aventis Pharma Sa Nouveaux taxoides, leur preparation et les compositions qui les contiennent
FR2745814B1 (fr) * 1996-03-06 1998-04-03 Rhone Poulenc Rorer Sa Nouveaux taxoides, leur preparation et les compositions pharmaceutiques qui les contiennent
FR2771092B1 (fr) 1997-11-18 1999-12-17 Rhone Poulenc Rorer Sa Procede de preparation de derives de la classe des taxoides
EP0982027A1 (en) * 1998-08-17 2000-03-01 Aventis Pharma S.A. Taxoid derivatives for treating abnormal cell proliferation of the brain
US6346543B1 (en) * 1998-08-17 2002-02-12 Aventis Pharma S.A. Use of a taxoid to treat abnormal cell proliferation in the brain
US6136989A (en) * 1998-12-30 2000-10-24 Phytogen Life Sciences, Incorporated Method for high yield and large scale extraction of paclitaxel from paclitaxel-containing material
US5969165A (en) * 1999-01-07 1999-10-19 508037 (Nb) Inc. Isolation and purification of paclitaxel and other related taxanes by industrial preparative low pressure chromatography on a polymeric resin column
ATE256117T1 (de) * 1999-05-17 2003-12-15 Bristol Myers Squibb Co Neue umsetzungsbedingungen für die spaltung von silylethern bei der herstellung von paclitaxel (taxol(r)) und paclitaxel -analogen
ATE382624T1 (de) * 2001-11-29 2008-01-15 Daiichi Sankyo Co Ltd Kristalle von taxanderivaten und verfahren zu deren herstellung

Also Published As

Publication number Publication date
NZ545835A (en) 2009-10-30
NO2015013I2 (no) 2015-04-22
EP1667986A1 (fr) 2006-06-14
HK1093340A1 (zh) 2007-03-02
BE2013C036I2 (enExample) 2023-12-14
BRPI0414492A8 (pt) 2019-01-15
FR13C0037I2 (fr) 2015-11-20
RU2342373C2 (ru) 2008-12-27
CR8292A (es) 2008-10-15
AR045667A1 (es) 2005-11-02
ZA200602255B (en) 2007-07-25
LU92172I2 (fr) 2013-05-21
RU2006113122A (ru) 2006-08-27
LU92172I9 (enExample) 2019-01-03
CA2539309A1 (fr) 2005-03-31
RS20060189A (sr) 2008-06-05
MXPA06002639A (es) 2006-06-05
FR2859996A1 (fr) 2005-03-25
IL174240A0 (en) 2006-08-01
KR20060072147A (ko) 2006-06-27
TNSN06086A1 (en) 2007-10-03
TWI382022B (zh) 2013-01-11
UA87115C2 (ru) 2009-06-25
US20050065138A1 (en) 2005-03-24
MY136668A (en) 2008-11-28
NO335997B1 (no) 2015-04-20
DK1667986T3 (da) 2013-05-06
TW200524891A (en) 2005-08-01
SI1667986T1 (sl) 2013-05-31
WO2005028462A1 (fr) 2005-03-31
MEP11708A (en) 2010-06-10
NO20061714L (no) 2006-04-19
PL1667986T3 (pl) 2013-06-28
RS54614B1 (sr) 2016-08-31
CN1849311A (zh) 2006-10-18
KR101123588B1 (ko) 2012-03-22
MA28045A1 (fr) 2006-07-03
AU2004274212A1 (en) 2005-03-31
PA8612401A1 (es) 2005-08-04
BRPI0414492A (pt) 2006-11-14
CN100429207C (zh) 2008-10-29
ME00054B (me) 2011-02-10
IL174240A (en) 2010-12-30
JP5010279B2 (ja) 2012-08-29
CY2013016I1 (el) 2018-01-10
US7241907B2 (en) 2007-07-10
CY1114575T1 (el) 2016-10-05
JP2007505866A (ja) 2007-03-15
FR2859996B1 (fr) 2006-02-03
ES2403149T4 (es) 2013-06-24
CY2013016I2 (el) 2018-01-10
ES2403149T3 (es) 2013-05-14
HUS1300025I1 (hu) 2016-08-29
PT1667986E (pt) 2013-04-24
FR13C0037I1 (fr) 2013-09-08
AU2004274212B2 (en) 2010-03-04
EP1667986B1 (fr) 2013-01-16
HRP20130322T1 (en) 2013-07-31
NO2015013I1 (no) 2015-05-04

Similar Documents

Publication Publication Date Title
PY2040196A (es) Uso de cannabidiol en el tratamiento del síndrome de dravet
BR112018067520A2 (pt) recipiente de substâncias hidropônicas flexível
WO2005065242A3 (en) Method of treating cancer using platelet releasate
UA95903C2 (ru) Транс-каротиноиды, их синтез, лекарственная форма и применение
AR072003A1 (es) Efectos antitumorales de combinaciones cannabinoides
PE20070244A1 (es) Biotejido de colageno derivado de placenta para el tratamiento de ulceras en la pierna
BRPI0408388A (pt) compostos de benzopirano úteis no tratamento de patologias inflamatórias
EA201001283A1 (ru) Комбинация витамина d и 25-гидроксивитамина d3
GT200500229A (es) Compuestos orgánicos
EA201001288A1 (ru) Лечение гипертонии 25-гидроксивитамином d3
CL2004001409A1 (es) Compuestos derivados de heterociclos biciclicos, sus sales; composicion farmaceutica; procedimientos de preparacion; y su uso para preparar un medicamento para tratar tumores, enfermedades de las vias respiratorias y del pulmon, del tracto gastrointe
MX2024009117A (es) Inhibidores de hsd17b13 sustituidos con 2 tiazoles y usos de los mismos
BR112012032385A2 (pt) método e aparelho de banho de pressão de névoa de gás de dióxido de carbono
CL2019003329A1 (es) Agente de suministro de hierro divalente.
BR0111683A (pt) Remédios para doenças alérgicas e processo de produção do mesmo
CN103275090A (zh) 一种酶法水解结合闪式提取快速从松针中提取脂溶性叶绿素的方法
Cheragh et al. Effect of Tetraselmis suecica microalgae isolated from the Persian Gulf on the expression level of AKT/mTOR genes in the liver cancer cell line, Huh7
DE602007002530D1 (de) Eiskonfekt
CL2013003225A1 (es) Sistema de agente de control biológico (bca) que comprende momias de chanchitos blancos de la familia pseudococcidae, desprovistos de extremidades y cubierta cerosa, los cuales están parasitados por avispas endo-parasitarias; método para producir dicho sistema de bca; método para controlar infestaciones de chanchitos blancos en plantas; y producto.
BRPI0803783A2 (pt) processo para moer sementes de soja e usina para tal processo
BR112012012493A8 (pt) método para o tratamento de fluxos de líquido em uma fábrica de pasta química
CN106137936A (zh) 蓝莓精华护肤液及其制备方法
CN207370018U (zh) 一种蜂蜜加工装置
UY28543A1 (es) Mezclas fungicidas para combatir patógenos del arroz
AR080667A1 (es) Un nutriente para plantas que se obtienen de la cascara del arroz y un proceso de preparacion del mismo

Legal Events

Date Code Title Description
FC Refusal